We found that the IDH1 inhibitor ivosidenib functions as an HR repair inhibitor by targeting YTHDC2, and a combination treatment of ivosidenib and PARPi Olaparib produced synergistic anti-tumor effects in BRCA1/2-proficient cancer cells. Here, YTHDC2 is linked to cancer.